Skip to main content
56°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences, Inc. - Common Stock
(NQ:
ENSC
)
2.215
+0.045 (+2.05%)
Streaming Delayed Price
Updated: 2:44 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 13, 2025
Via
ACCESS Newswire
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
May 12, 2025
Via
ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
April 24, 2025
Via
ACCESS Newswire
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
Via
ACCESS Newswire
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
Via
ACCESS Newswire
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
February 05, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
January 22, 2025
Via
ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
January 08, 2025
Via
ACCESSWIRE
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
April 23, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
April 15, 2025
Via
ACCESS Newswire
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 31, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
March 18, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
December 10, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
December 04, 2024
Via
ACCESSWIRE
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
November 26, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
November 12, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
March 05, 2025
Via
ACCESS Newswire
Ensysce Biosciences Regains Full Compliance with Nasdaq
December 23, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
December 03, 2024
Via
ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
November 07, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
October 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
September 24, 2024
Via
ACCESSWIRE
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
September 19, 2024
Via
ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
September 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
October 02, 2024
Via
ACCESSWIRE
Ensysce Biosciences Receives Notice from Nasdaq
September 27, 2024
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
August 29, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
August 27, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
August 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
August 14, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
